F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comSun Pharma Advanced Research Company Ltd (SPARC) is known for pioneering pharmaceutical innovation in India. As an R&D focused subsidiary of Sun Pharmaceutical Industries, SPARC leverages advanced technologies and strategic research pipelines for specialty medicines, establishing its role in the healthcare sector. In this article, we’ll analyze SPARC’s latest share price, performance metrics, and forecast its potential targets through 2030, offering insights for retail and institutional investors.
Let’s dive into SPARC’s business overview, financial details, and future share price projections.
| Detail | Value |
|---|---|
| Open | ₹133.99 |
| Previous Close | ₹133.26 |
| Day's High | ₹145.45 |
| Day's Low | ₹133.27 |
| Market Capitalization | ₹4,666 Cr |
| VWAP | ₹142.75 |
| Beta | 1.47 |
| UC Limit | ₹159.91 |
| LC Limit | ₹106.60 |
| 52-Week High | ₹241.00 |
| 52-Week Low | ₹109.30 |
| Face Value | ₹1 |
| All Time High | ₹593.93 |
| All Time Low | ₹35.17 |
| 20D Avg Volume | 239,665 |
| 20D Avg Delivery (%) | 43.4 |
| Book Value Per Share | -₹2.38 |
These figures highlight SPARC’s current market position, reflecting moderate volatility, strong trading volumes, and significant historical price ranges.
SPARC specializes in drug discovery and development, focusing on innovative solutions for complex, unmet medical needs. The company is governed by a strong promoter group and operates across major therapeutic areas, including oncology, neurology, and ophthalmology, with a robust pipeline of research compounds.
Key Highlights:
Leader in pharmaceutical R&D in India
Strategic focus on specialty medicine platforms
High promoter holding ensures stability and confidence
Partnerships with global healthcare firms for co-development
Volatile price movements due to research-driven business model
| Investor Type | Holding (%) |
|---|---|
| Promoters | 65.67% |
| Retail and Others | 31.52% |
| Foreign Institutions | 1.76% |
| Mutual Funds | 1.01% |
| Other Domestic Institutions | 0.03% |
The shareholding data reveals a stable promoter base, minimal institutional participation, and robust retail interest.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 135 | 155 |
| 2026 | 160 | 185 |
| 2027 | 175 | 215 |
| 2028 | 190 | 240 |
| 2029 | 210 | 265 |
| 2030 | 235 | 295 |
These targets are projected based on SPARC’s ongoing research projects, volatility trends, earnings outlook, and technical price behavior .
SPARC’s 2025 outlook is neutral-to-positive, supported by strong trading volumes, high promoter ownership, and anticipated regulatory milestones.
Why?
Multiple clinical trials in advanced stages
High market interest and liquidity
Stable operational performance in specialty pharma
Investment Advice: Ideal for partial entries on corrections and accumulation for those seeking research-fueled growth .
Moderate growth is expected in 2026 as new drug launches fill revenue pipelines.
Why?
Entry of key molecules into commercialization
Increased global collaborations
Improved margin profile due to specialty launches
Investment Advice: Hold medium-term positions; track USFDA developments and quarterly updates .
A focus on exports and patent-driven products may boost SPARC’s valuation in 2027.
Why?
Success in export markets (US/EU)
High-value patents augmenting asset base
Recovery in global healthcare demand
Investment Advice: Reinvest dividends and keep exposure; monitor R&D spending and news flow .
By 2028, solid EPS growth and global recognition can drive share prices higher.
Why?
Expansion into new therapy areas
Operational leverage from successful drugs
Strengthened financial position
Investment Advice: Suitable for growth-oriented portfolios aiming for double-digit CAGR .
Strong innovation track record and global penetration position SPARC as a sectoral outperformer.
Why?
Robust financials and net profit improvement
Scaling of specialty brands
Expansion into emerging pharma markets
Investment Advice: Suggest staggered additions for multi-year holding horizons .
By 2030, SPARC may be recognized as a top innovation-centric pharma firm.
Why?
Diverse revenue channels (proprietary drugs, out-licensing)
High-capacity clinical development assets
Resilient leadership and stable governance
Investment Advice: Excellent for long-term, high-risk-high-reward allocations .
SPARC’s future outlook is promising owing to its R&D focus, stable promoter backing, and potential for blockbuster drug commercialization. However, investors should weigh volatility risks and regulatory factors.
Key Reasons to Invest:
Innovation-driven growth strategy
High promoter holding ensures stability
Potential for strategic alliances and licensing deals
Exposure to specialty pharma, a high-growth sector
High volatility due to clinical trial outcomes and regulatory delays
Dependency on successful drug launches and patent approvals
Risks from competition and global market slowdowns
Always consult a SEBI-registered financial advisor for tailored investment decisions.
Sun Pharma Advanced Research Company Ltd stands out for its innovative edge, robust promoter confidence, and potential for substantial capital appreciation. With a current price around ₹133.99-₹145.45, SPARC offers a mix of opportunity and risk, projected to reach ₹295 by 2030 for investors comfortable with healthcare sector volatility .
Stay updated with quarterly results, international collaborations, and regulatory announcements to maximize portfolio returns.
What is the next target of Sun Pharma Advanced Research Company Ltd?
The next price target is shaped by regulatory milestones and business developments; analysts track price bands and earnings surprises .
Is SPARC a good buy right now?
It depends on your risk appetite and belief in pharmaceutical innovation; consider market sentiment and recent clinical updates .
What will be the future outlook of SPARC?
SPARC’s growth relies on drug approvals, export traction, and successful research yield—long-term prospects look strong but volatile .
What is the share price target for SPARC in 2025?
Based on projections, the 2025 target is between ₹135 and ₹155 .
What is the current SPARC share price?
SPARC trades between ₹133.99 and ₹145.45 as of October 28, 2025 .
Is it a good time to buy SPARC shares now?
Buying now depends on technical trends, fundamental strength, and R&D news. Consider buying on dips for a long-term view .
Should I buy SPARC stock?
Consult your financial advisor to align SPARC investment with portfolio goals and risk tolerance .
How much has SPARC increased from its 52-week low?
SPARC has gained over 20% from its 52-week low of ₹109.30 .
How do I invest in SPARC?
Invest through NSE/BSE online platforms via authorized brokers .
What is SPARC’s shareholding pattern?
Majority held by promoters (65.67%), with strong retail presence and minimal institutional participation .
Disclaimer: This article is for educational purposes only. Please seek expert advice before making investment decisions.
Register & Login